Literature DB >> 17623759

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.

S G I Suliman1, A Gurlek, J V Byrne, N Sullivan, G Thanabalasingham, S Cudlip, O Ansorge, J A H Wass.   

Abstract

CONTEXT: Macroprolactinomas (MPRLs) may result in nonsurgical (spontaneous or dopamine agonist induced) cerebrospinal fluid (CSF) rhinorrhea; however, the incidence of and mechanisms underlying this phenomenon are poorly understood.
OBJECTIVE: The objective of the study was to determine the incidence of nonsurgical rhinorrhea and identify biochemical, radiological, and histopathological factors associated with leakage. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of MPRL patients (n = 114) was compared with patients with nonfunctioning pituitary adenoma (NFA) (n = 181) seen over a 19-yr period (1985-2004). MAIN OUTCOME MEASURES: Incidence of CSF rhinorrhea, factors predictive of leakage, and differential expression of candidate markers of invasiveness were measured.
RESULTS: Nonsurgical CSF rhinorrhea occurred in 8.7% of MPRLs (10 of 114) [2.6% spontaneous (three of 114), 6.1% dopamine agonist induced (seven of 114)], whereas no NFAs developed nonsurgical rhinorrhea. There was a clear male preponderance in MPRLs with nonsurgical rhinorrhea (males to females, 9:1, P = 0.008). Dopamine agonist resistance was more frequent in MPRLs with rhinorrhea than with MPRLs without rhinorrhea [30% (n = 10) vs. 5% (n = 104) P = 0.003]. Baseline prolactin levels, rate of prolactin decline in response to dopamine agonists, and tumor volume at diagnosis did not predict CSF leakage. Candidate markers of invasiveness, specifically the protease-activated receptor 1 and e-cadherin expression scores and tumor macrophage density, were not significantly different between groups; MPRL+CSF rhinorrhea (n = 6), MPRL without CSF rhinorrhea (n = 9), and NFAs (n = 9).
CONCLUSIONS: The incidence of nonsurgical CSF rhinorrhea in MPRL patients (8.7%) is higher than expected. Dopamine agonist resistance is more common in MPRLs with CSF rhinorrhea; however, whether this is a mechanistic relationship requires further study. Protease-activated receptor 1 expression, e-cadherin expression, and macrophage infiltration rates do not distinguish tumors with from those without CSF rhinorrhea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623759     DOI: 10.1210/jc.2007-0373

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Tension pneumocephalus after administration of two 0.25 mg cabergoline tablets in MEN1-related macroprolactinoma.

Authors:  Kazutaka Nanba; Takeshi Usui; Takuya Nakakuki; Akira Shimatsu
Journal:  BMJ Case Rep       Date:  2013-06-07

Review 2.  Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Authors:  Tomáš Česák; Pavel Poczos; Jaroslav Adamkov; Jiří Náhlovský; Petra Kašparová; Filip Gabalec; Petr Čelakovský; Ondrej Choutka
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 3.  Surgery for prolactinomas: a better choice?

Authors:  Jürgen Honegger; Isabella Nasi-Kordhishti; Nuran Aboutaha; Sabrina Giese
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

4.  Spontaneous cerebrospinal fluid rhinorrhoea as the presenting feature of an invasive macroprolactinoma.

Authors:  Satveer Kaur Mankia; Ruwan Alwis Weerakkody; Shanelle Wijesuriya; Narayanan Kandasamy; Francis Finucane; Mathew Guilfoyle; Nagui Antoun; John Pickard; Mark Gurnell
Journal:  BMJ Case Rep       Date:  2009-05-21

Review 5.  Cabergoline in acromegaly.

Authors:  Emmanuelle Kuhn; Philippe Chanson
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Giant prolactinoma in children and adolescents: a single-center experience and systematic review.

Authors:  Sandeep Kumar; Vijaya Sarathi; Anurag Ranjan Lila; Manjeetkaur Sehemby; Saba Samad Memon; Manjiri Karlekar; Shilpa Sankhe; Virendra A Patil; Nalini Shah; Tushar Bandgar
Journal:  Pituitary       Date:  2022-07-18       Impact factor: 3.599

7.  Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.

Authors:  Eun-Hee Cho; Sang Ah Lee; Ji Youn Chung; Eun Hee Koh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Min-Seon Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

8.  CSF Rhinorrhea Following Medical Treatment for Prolactinoma: Management and Challenges.

Authors:  Arivazhagan Arimappamagan; Nishanth Sadashiva; Sandeep Kandregula; Dhaval Shukla; Sampath Somanna
Journal:  J Neurol Surg B Skull Base       Date:  2019-01-21

9.  SPONTANEOUS CEREBROSPINAL FLUID LEAK AFTER INITIATION OF DOPAMINE AGONIST THERAPY IN MACROPROLACTINOMAS: TWO CASE REPORTS AND A LITERATURE REVIEW.

Authors:  Jonea Lim; Mitali Talsania; Madona Azar
Journal:  AACE Clin Case Rep       Date:  2020-03-04

10.  Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles.

Authors:  Derek Yecies; Abdulrazag Ajlan; John Ratliff; Jennifer Ziskin; Peter Hwang; Hannes Vogel; Laurence Katznelson; Griffith Harsh
Journal:  J Neurol Surg Rep       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.